Ibrance
palbociclib · CDK4/6 Inhibitor
Indications & Uses
Treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant.
Contraindications
Hypersensitivity to palbociclib or any product components.
Side Effects & Warnings
Neutropenia, leukopenia, fatigue, infections, epistaxis, anemia, stomatitis, alopecia, diarrhea, thrombocytopenia, and nausea.
Drug & Dietary Interactions
Strong CYP3A inhibitors (ketoconazole, clarithromycin) increase palbociclib exposure; strong CYP3A inducers (rifampin, St. John's wort) decrease exposure.
Regulatory & Prescribing Information
FDA Approved NDA 207103. Monitor complete blood count prior to start and at beginning of each 28-day cycle.
For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.
Ask About This Medication
Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.